Analyst Ratings For ArQule, Inc. (NASDAQ:ARQL)
Today, Roth Capital set its price target on ArQule, Inc. (NASDAQ:ARQL) to $7.00 per share.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on ArQule, Inc. (NASDAQ:ARQL) is Buy with a consensus target price of $7.00 per share, a potential 80.88% upside.
Some recent analyst ratings include
- 6/12/2018-ArQule, Inc. (NASDAQ:ARQL) has coverage initiated with a Outperform rating and $7.00 price target
- 4/5/2018-ArQule, Inc. (NASDAQ:ARQL) gets upgraded to Outperform by Leerink Swann
- On 5/30/2018 Value Fund L P Biotechnology, Insider, sold 1,035,939 with an average share price of $5.00 per share and the total transaction amounting to $5,179,695.00.
- On 5/18/2018 Paolo Pucci, CEO, bought 15,000 with an average share price of $3.39 per share and the total transaction amounting to $50,850.00.
- On 5/18/2018 Ran Nussbaum, Director, bought 8,611 with an average share price of $3.29 per share and the total transaction amounting to $28,330.19.
- On 5/14/2018 Patrick J Zenner, Director, bought 8,446 with an average share price of $2.96 per share and the total transaction amounting to $25,000.16.
- On 5/10/2018 Paolo Pucci, CEO, bought 1,300 with an average share price of $2.64 per share and the total transaction amounting to $3,432.00.
- On 5/10/2018 Ronald M Lindsay, Director, bought 23,900 with an average share price of $2.67 per share and the total transaction amounting to $63,813.00.
- On 4/18/2018 Value Fund L P Biotechnology, Insider, sold 2,230,373 with an average share price of $3.10 per share and the total transaction amounting to $6,914,156.30.
About ArQule, Inc. (NASDAQ:ARQL)
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
Recent Trading Activity for ArQule, Inc. (NASDAQ:ARQL)
Shares of ArQule, Inc. closed the previous trading session at 3.87 −0.32 7.64% with 1944800 shares trading hands.